Completed × Osteosarcoma × CNS × Clear all
NCT02162732 2025-11-03

Molecular-Guided Therapy for Childhood Cancer

Milton S. Hershey Medical Center

Phase NA Completed
186 enrolled 12 charts
NCT03213665 2025-01-27

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
20 enrolled 12 charts
NCT03213678 2025-01-27

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
18 enrolled 12 charts
NCT03220035 2025-01-27

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
4 enrolled 12 charts
NCT03233204 2024-12-11

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
6 enrolled 12 charts
NCT03526250 2024-11-01

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
23 enrolled 11 charts
NCT00445965 2024-04-04

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
78 enrolled 11 charts
NCT00019630 2024-03-04

Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
NCT02223052 2020-05-12

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Celgene

Phase 1 Completed
89 enrolled
NCT00003657 2017-01-20

High-dose ICE With Amifostine

Dana-Farber Cancer Institute

Phase 2 Completed
24 enrolled
NCT00024258 2015-11-25

Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
22 enrolled 6 charts
NCT00020150 2015-04-29

Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
NCT00003597 2014-07-24

Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors

Children's Oncology Group

Phase 1 Completed
16 enrolled
NCT00538850 2014-03-05

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

INSYS Therapeutics Inc

Phase 3 Completed
130 enrolled 9 charts
NCT00014456 2013-08-28

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors

Dartmouth-Hitchcock Medical Center

Phase 1 Completed
35 enrolled
NCT00003022 2013-07-03

Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
NCT00091182 2013-06-05

Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment

National Cancer Institute (NCI)

Phase 2 Completed
180 enrolled
NCT00101270 2013-06-05

Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled